Odyral (Dorzolamide)

Dorzolamide, the active ingredient in Odyral, is a carbonic anhydrase inhibitor presented as a topical ophthalmic solution for ocular use. It is employed to lower intra‑ocular pressure in various forms of glaucoma and ocular hypertension. GNH USA supplies Odyral as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Dorzolamide acts on the ocular fluid‑production pathway to manage elevated intra‑ocular pressure. - Primary open‑angle glaucoma: reduces intra‑ocular pressure to slow disease progression. - Ocular hypertension: lowers pressure to prevent conversion to glaucoma. - Secondary glaucoma (e.g., pseudoexfoliative): helps control pressure when other agents are insufficient.

Adverse reactions may occur with ocular administration of dorzolamide.

Common Side Effects: - Burning or stinging sensation in the eye - Transient blurred vision - Altered taste sensation - Headache - Ocular discomfort or redness - Mild eye irritation

Serious or Rare Side Effects: - Severe allergic reaction (e.g., angio‑edema, anaphylaxis) - Stevens‑Johnson syndrome or toxic epidermal necrolysis - Corneal edema or ulceration - Persistent ocular inflammation - Systemic metabolic acidosis (rare) - Vision loss due to severe ocular complications

When using dorzolamide, certain precautions should be observed. - Assess intra‑ocular pressure regularly: ensure therapeutic effectiveness. - Monitor for signs of hypersensitivity: discontinue if severe reaction occurs. - Use with caution in patients with sulfonamide allergy: cross‑reactivity possible. - Avoid contact lens wear during treatment: may cause lens discoloration or irritation. - Evaluate renal and hepatic function: dose adjustment may be required in impairment. - Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Dorzolamide may interact with other ocular or systemic agents.

Major Interactions (Avoid): - Systemic carbonic anhydrase inhibitors (e.g., acetazolamide): increased risk of systemic acidosis. - Sulfonamide antibiotics (e.g., sulfamethoxazole): heightened hypersensitivity potential.

Moderate Interactions (Monitor Closely): - Topical beta‑blockers (e.g., timolol): additive intra‑ocular pressure reduction may require monitoring. - Prostaglandin analogues (e.g., latanoprost): combined effect may enhance pressure lowering. - Non‑steroidal anti‑inflammatory eye drops: may increase ocular irritation. - Systemic diuretics: possible electrolyte disturbances when combined.